Clinical Trial Details

TWILIGHT

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT)

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Coronary Artery Disease
Study Type: Interventional
Phase: Phase IV
Study Start Date: 05/16/2016
Study Completion Date: TBD

This study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to the heart. This study will look to determine the effectiveness and safety of ticagrelor alone, compared to ticagrelor plus aspirin in reducing clinically relevant bleeding and in reducing ischemic adverse events among high-risk patients who have had a percutaneous intervention with at least one drug-eluting stent.

NCT Number

NCT02270242

Principal Investigator(s)

Thomas Wang, MD

Sponsor(s)

Icahn School of Medicine at Mount Sinai

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female